BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

The following is a summary of “Can self-testing be enhanced to hasten safe return of healthcare workers in pandemics? Random ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...

BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...

State of play: Currently, providers can make educated guesses about how sick a patient might get from COVID based on ...

A genomic test developed by researchers to rapidly detect almost any kind of pathogen -- virus, bacteria, fungus or parasite -- has proved successful after a decade of use.

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...